Perioperative Treatment of Parkinsonian Patients With Parenteral Amantadine

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-01-31

Study Completion Date

2011-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether administrating of Amantadine (a dopamine agonist) to patients suffering from Parkinson disease during the perioperative period is safe, and to asses potential benefits of this treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Multi-Center, Observational Safety Registry of Subjects With Idiopathic Parkinson's Disease Previously Treated With Intraputaminal Infusion of Liatermin

NCT00148369

Idiopathic Parkinson's Disease

COMPLETED

An Evaluation of the Pharmacokinetics and Pharmacodynamics of AP09004 in Patients With Parkinson's Disease

NCT00918177

Parkinson's Disease

COMPLETED PHASE2

Pilot Study of Maintenance Therapy With Intravenous AMANTADINE

NCT01190553

Parkinson Disease

UNKNOWN NA

Quantification of the Antidyskinetic Effect of Amantadine and Topiramate in Parkinson's Disease

NCT00794313

Parkinson's Disease

TERMINATED NA

Is Long-term Use of Amantadine Effective in PD?

NCT04260581

Parkinson Disease

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson Disease Perioperative Care

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A

Group Type EXPERIMENTAL

Amantadine

Intervention Type DRUG

IV Amantadine 200mg \*1/d at the beginning of surgery and 24 hours following surgery

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Amantadine

IV Amantadine 200mg \*1/d at the beginning of surgery and 24 hours following surgery

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

PK MERZ

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient with a diagnosis of Parkinson Disease refered for surgery at our institution.

Exclusion Criteria

* Cardiac and neurosurgical procedures
* Inability to sign informed Consent
* allergy to Amantadine
* Congestive heart failure
* Arrythmia (including bradycardia below 55 bpm)
* renal failure (creatinin above 1.5)
* If a patient will develop agitation or delirium lasting longer then 8 hours he will not receive the second dose of amantadine.

Eligible Sex

ALL

Accepts Healthy Volunteers

No